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Abstract
Purpose The Drug Burden Index (DBI) is a non-invasive
method to quantify patients’ anticholinergic and sedative drug
burden from their prescriptions. This systematic review aimed
to summarise the evidence on the associations between the
DBI and clinical outcomes and methodological quality of
studies.
Methods A search in PubMed and Embase (search terms:
‘drug’, ‘burden’, and ‘index’) was performed and experts were
contacted. We excluded publications that did not report em-
pirical results or clinical outcomes. Methodological quality
was assessed using the Newcastle-Ottawa Scale. Potential
omissions of relevant clinical outcomes and populations were
studied.
Results Of the 2998 identified publications, 21 were eligible.
Overall, methodological quality of studies was good. In all but
one study, adjustment was made for prevalent co-morbidity.
The DBI was examined in diverse older individuals, i.e. both
males and females from different settings and countries.
However, no studies were conducted in other relevant patient
groups, e.g. psychiatric patients. Exposure to anticholinergic
and sedative drugs was thoroughly ascertained, though the
specific calculation of the DBI differed across studies.
Outcomes were assessed frommedical records, record linkage
or validated objective tests or questionnaires. Many studies
found associations between the DBI and outcomes including
hospitalisation, physical and cognitive function. Cognitive
function and quality of life were understudied and the number
and scope of longitudinal studies was limited.
Conclusions An accumulating body of evidence supports the
validity of the DBI. Longitudinal studies of cognitive function
and quality of life and in other patient groups, e.g. psychiatric
patients, are warranted.
Keywords Antimuscarinic agents . Hypnotics and sedatives .
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Introduction
Drugs with anticholinergic and sedative properties are pre-
scribed in over a quarter of older patients [1, 2] despite their
likelihood to increase patients’ physical and cognitive impair-
ment [3–5]. In 2007, Hilmer and colleagues published the
Drug Burden Index (DBI) [6], a linear additive model that
quantifies cumulative anticholinergic and sedative drug load
for patients with polypharmacy:
DBI ¼ ∑ D
δ þ D
where D is the daily dose of an individual drug and δ usually
represents the minimum recommended daily dose of that in-
dividual drug. The sigma sign (∑) indicates that the DBI is the
sum score of prescribed drugs with probable anticholinergic
and sedative properties for each patient. Compared to other
methods of estimating patients’ anticholinergic and sedative
drug load such as serum anticholinergic activity (SAA) [7]
and related scales such as the Anticholinergic Risk Scale
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(ARS) [8] and the Anticholinergic Drug Scale (ADS) [9], the
DBI has two advantages. First, it is non-invasive as it is cal-
culated from drug prescriptions. Unlike SAA, the DBI does
not require blood withdrawal. Second, the DBI takes the dos-
age of each anticholinergic and sedative drug into account
whereas the ARS and ADS scales do not. Thus, these two
advantages clearly favour the DBI over other measures as a
tool for the routine screening of anticholinergic and sedative
burden in the process of deprescribing of anticholinergic and
sedative drugs by pharmacists and physicians [10–12].
A growing body of studies conducted in Australia, North
America, and Europe have examined associations between the
DBI and clinical outcomes. Recently, Kouladjian et al. [13]
discussed these findings in a comprehensive overview of stud-
ies, thereby providing insight into the clinical and theoretical
applications of the DBI. There is increasing interest in meth-
odological issues about how to estimate exposure to anticho-
linergic and sedative drugs. [14–17] Two recent systematic
reviews evaluated the scales that are currently used to quantify
the anticholinergic and sedative drug burden as well as asso-
ciated clinical outcomes. [18, 19] These systematic reviews
found drugs with anticholinergic properties to increase the
risks of cognitive impairment, falls, functional outcomes and
all-cause mortality in older adults.
The current systematic review aims to assess the scope and
quality of studies about the DBI focusing on methodology,
patient populations and outcomes. In doing so, the current
systematic review aims to complement these previous system-
atic reviews. Such an assessment is needed to reflect on cur-
rent knowledge about the associations between patients’ DBI
values and clinical outcomes, to provide advice on methodo-
logical requirements for future studies and to identify knowl-
edge gaps about clinically relevant outcomes.
Material and methods
Data sources and search strategy
We conducted a search and extraction according to the
PRISMA statement [20] in September 2015. We searched
for all English publications about original studies of the
DBI since its launch in 2007 with the search term: Drug
[All Fields] AND Burden [All Fields] AND Index [All
Fields] AND [B2007/01/01^[PDAT] : B2015/09/
30^[PDAT]]) in PubMed and Embase and in the reference
lists of initially found publications. Thus, the search was
not limited to studies conducted in older adults. Authors
whose publications were not electronically available were
contacted and requested to provide their publications.
Lastly, we contacted experts from relevant publications to
identify other studies.
Study screening and selection
Publications were included if they reported empirical results
and associations between the DBI and clinical outcomes.
Publications were excluded if they were not available either
electronically or from the authors. Publications were not ex-
cluded if the DBI calculation was based on only anticholiner-
gic or sedative drugs.
Data extraction and synthesis
Eligibility, methodological quality and study outcomes were
extracted by HW and reviewed by HVDM. In case of dis-
agreements between HW and HVDM, final decisions were
made by KT. For studies in which separate DBIs were calcu-
lated for anticholinergic and sedative drugs, results of both
DBIs were considered. If studies reported both a standard
overall DBI calculated for anticholinergic and sedative drugs
and DBIs calculated separately for anticholinergic and seda-
tive drugs, only results of the standard overall DBI were
considered.
All eligible studies were rated for their methodological
quality using the Newcastle-Ottawa Scale [NOS] [21]. The
NOS awards stars with regard to selection of participants,
i.e. representativeness (1 star), and selection of participants
not exposed to anticholinergic and sedative drugs (controls)
(1 star), ascertainment of anticholinergic and sedative expo-
sure (1 star), comparability of participants with high and low
DBI values, i.e. by taking the most important confounding
factor (1 star) and additional confounding factors (1 star) into
account, and outcomes, i.e. whether these were assessed in a
blind manner (1 star). Furthermore, for longitudinal studies,
whether incidence of outcomes was assessed or whether their
absence at baseline was verified or adjusted for (1 star), and
adequacy of follow-up, i.e. whether length of follow-up was
adequate (1 star), and whether the amount of attrition, and
presence of differential attrition or selective loss to follow-
up, e.g. more loss to follow-up among patients with higher
baseline frailty, was assessed and acceptable (1 star).
Furthermore, we also assessed how often relevant clinical out-
comes were studied and potential omissions of relevant clin-
ical outcomes, as well as the specific patient populations that
were studied.
Results
The search resulted in 2998 publications. After exclusion of
2954 publications based on title and abstract, and excluding
23 publications after reviewing their full texts, 21 eligible
publications were included in the review (see flowchart in
Fig. 1). Experts confirmed there were no other eligible publi-
cations. Owing to the substantial heterogeneity with regard to
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clinical outcomes, classification of DBI values, and study de-
sign, we decided that a qualitative synthesis of the literature
was more suitable than a quantitativemeta-analysis. Key char-
acteristics of eligible publications are presented in Table 1.
Selection of participants and populations studied
Ratings of the methodological quality of eligible studies
are presented in Online Resource 1. All studies focused
on older geriatric patients as the mean age of study popu-
lations ranged from 72 to 86 years. Furthermore, sampling
in several studies was found to be restricted to a single
urban area [25, 27, 31, 36], to participants from RCTs
[23, 39–41], to either female [24] or male participants
[26, 28, 32] or to a single or two recruitment sites [22,
29, 30]. Other studies were more representative of geriatric
patients [6, 34, 35], very large [33], or even studied a na-
tional sample of older individuals [37, 38]. Overall repre-
sentativeness of studies was good as individual studies in-
cluded both male and female participants were conducted
in different settings, i.e. hospital wards, residential aged
care facilities or community-dwelling older people.
Studies were also conducted in various countries although
these were predominantly countries from Australasia,
Europe and North America (Table 1). Individuals who
were not exposed to anticholinergic and sedative drug load
were consistently drawn from the same population as ex-
posed individuals.
Ascertainment of anticholinergic and sedative exposure
Exposure to drugs was thoroughly ascertained in the
majority of studies, thus providing a substantial base
for the DBI calculation. Drug exposure was assessed
through participants’ self-report during a structured in-
terview and a verification of participants’ answers
through inspection of prescription forms and packages
by qualified assessors [6, 24–28, 32, 34–36], through
dispensing data on medication [33, 37, 38] or from
clinical records [22, 23, 29–31, 39–41]. In some studies,
the DBI was calculated for anticholinergic and/or seda-
tive drugs separately [24, 30, 35].
However, some caveats were also observed. Although
the grounds were mentioned for classifying drugs as being
anticholinergic or sedative, none of the lists of DBI drugs
has been published. Furthermore, studies conducted in the
USA used the minimum recommended daily dose as ap-
proved by the US Food and Drug Administration [6]
while studies outside the USA used other national refer-
ence sources to estimate the δ or the minimum daily dose.
Possible differences between studies and the influence of
such differences on associations between patients’ DBI
values and clinical outcomes could not be assessed. One
study examined the relationship between the DBI and
SAA but found no significant relationship [30]. Other
studies compared the DBI with other anticholinergic scales
[35] or the Beers criteria [27].
Records idenﬁed in PubMed, Embase, reference lists 
of publicaons and through experts
N = 3697
Full-text arcles assessed for eligibility
N = 44
Full-text arcles excluded: N = 23
13 did not report empirical results
8 did not report associaons between DBI 
and clinical outcomes 
2 publicaons adopted a diﬀerent formula 
/ measure
Studies included in qualitave synthesis
N = 21
Removal of duplicate records
N = 699
Records aer duplicates removed
N = 2998
Removal of records based on Title/Abstract
N = 2954
Fig. 1 Flowchart of
identification and assessment of
eligibility of DBI publications
Eur J Clin Pharmacol (2017) 73:257–266 259
Comparability of participants with high and low DBI
values
In all but one study, [35] adjustment was made for preva-
lent co-morbidity. In all studies, age was adjusted for in
relevant analyses and studies that included men and women
also adjusted for sex. Several of these studies also adjusted
for cognitive impairment, or presence of dementia [22, 23,
25–27, 29, 30, 36, 39, 40] and depressive or other
neuropsychiatric symptoms including sleep problems [23,
24, 26–28, 34, 39, 40]. If cognitive function was the out-
come, analyses had most of the time been adjusted for age
[6, 24, 28, 39] and educational level [6, 24, 28], which are
important determinants of cognitive function. Five studies
adjusted for prescribed drugs other than those included in
the DBI calculation [22, 24, 29, 40, 41]. In one study,
patients and controls were matched for age, sex and region
of residence [33].
Table 1 Characteristics of
eligible publications of cross-
sectional and longitudinal studies
(N = 21)
Publication











Best et al. 2013 [22] 329 I, Australia Hospital
wards
62 85 [±7] 8 [±4]
Bosboom et al.
2012 [23]
226 II, Australia RACF 75 86 [±8] 10 [±4]
Cao et al. 2008 [24] 932 III, USA Community 100 78 [71–86]a –
Gnjidic et al. 2012a [25] 700 IV, Finland Community 69 81 [±5] 5 [±3]
Gnjidic et al. 2009 [26] 1705 V, Australia Community 0 77 [±6] 4 [±3]
Gnjidic et al. 2012b [27] 115 VI, Australia Community 73 82 [±6] 5 [±3]
Gnjidic et al. 2012c [28] 987 V, Australia Community 0 77 [±6] 4 [±3]
Hilmer et al. 2007 [6] 3075 VIII, USA Community 52 74 [±3] 3 [±3]
Lowry et al. 2012 [29] 362 X, UK Geriatric
wards
59 84 [±7] 7 [5–9]a
Mangoni et al.
2013 [30]
71 XI, Holland Hospital
wards




337 XIV, France Geriatric
wards
65 85 [±7] 7 [±4]
Gnjidic et al. 2012d [32] 1662 V, Australia Community 0 77 [±5] 4 [±3]
Gnjidic et al. 2014 [33] 33,206 VII, Finland Community 67 79 [±9] –
Hilmer et al. 2009 [34] 2172 VIII, USA Community 53 73 [±3] –
Kashyap et al. 2014 [35] 102 IX, Canada Community 84 72 [±7] 7 [±4]
Lönnroos et al.
2012 [36]
339 IV, Finland Community 68 81 [±5] 5 [±3]
Nishtala et al. 2014 [37] 537,387 XII, New
Zealand





Community 55 75 [±8] 6 [±4]
Wilson et al. 2010 [39] 602 XIII, Australia RACF 71 86 [±6] 6 [±3]
Wilson et al. 2011 [40] 602 XIII, Australia RACF 71 86 [±6] 6 [±3]
Wilson et al. 2012 [41] 602 XIII, Australia RACF 71 86 [±6] 6 [±3]
Data sources: I, Concord Repatriation General Hospital Sydney New South Wales Australia; II, DIRECT Study
Beer C et al. Trials 2010; 11: 63; III, Medicare beneficiaries Baltimore City and Baltimore Country, Maryland; IV,
GeMS study Rikala et al., Drugs Aging. 2010; 27:337–49; V, CHAMP, Cumming et al., Int J Epidemiol 2008; 38:
374–8; VI, Self-care retirement villages in Sydney, Australia; VII, Linkage of Finnish National Prescription and
Special Reimbursement Registers with Finnish Hospital Discharge Register; VIII, Health ABC study community-
resident Medicare recipients, Pittsburgh, Pennsylvania and Memphis, Tennessee; IX, Patients of incontinence
clinics, Montreal and Sherbrooke areas of Quebec, Canada; X, Two acute geriatric medicine units from Aberdeen
Royal Infirmary and Woodend Hospital, NHS Grampian, Aberdeen, Scotland, United Kingdom; XI, Academic
Medical Centre, Amsterdam, the Netherlands; XII, Pharmaceutical Claims Data Mart [Pharms] of the
Pharmaceutical Management Agency [PHARMAC] and data from the Ministry of Health of New Zealand;
XIII, Multicentre cluster-randomised controlled trial of RACFs residents in the Northern Sydney Central Coast
Health [NSCCH] service area, Australia; XIV Consecutive sample of hospitalised patients of three geriatric
hospitals, University Hospital of Lyon, France
RACF residential aged care facility
aMedian value with interquartile range
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Outcomes
Outcomes were usually assessed through record linkage, e.g.
national prescription or reimbursement registers and hospital
discharge registers [30, 33, 36–38], medical records and
clinical notes [22, 31, 40, 41] or through objective tests
(see below).
Tables 2 and 3 present the associations found in different
studies between the DBI and various clinical outcomes.
Across different studies, the DBI was either studied as a con-
tinuous or categorised measure.
The majority of associations of the DBI with mortali-
ty, hospital isat ion, fal ls , physical funct ion and
(instrumental) activities of daily living ([I]ADL), cogni-
tive function and quality of life were statistically signif-
icant. Three of the five studies which assessed mortality
and five of the six studies assessing hospital admissions
found positive associations between the DBI and these
outcomes. Higher DBI values were consistently found
to be associated with increased fall risk. Impairments of
physical function and IADL were examined in nine stud-
ies. Most studies consistently showed a higher DBI to be
Table 2 Associations between the Drug Burden Index [DBI] and mortality, healthcare utilisation and falls
Outcome category S/NS Outcome DBI categorisation Statistic
Mortality
Dauphinot et al., 2014 [31] NS In-hospital mortality DBI DDD increase HR, 1.9 [95% CI: 0.8–4.4]a
Gnjidic et al., 2014 [33] S Mortality AD patients Continuous HR: 1.21 [95% CI: 1.09–1.33
]
S Mortality non-AD patients Continuous HR: 1.37 [95% CI: 1.20–1.56]
Nishtala et al., 2014 [37] S Mortality DBI [>0] HR: 1.29 [95% CI: 1.25–1.33]
Wilson et al., 2012 [41] NS Mortality DBI [0–1] HR: 1.13 [95% CI: 0.82–1.57]
NS Mortality DBI [≥1] HR: 1.19 [95% CI: 0.82–1.74]
Mangoni et al., 2013 [30] S 1-year mortality Anticholinergics HR: 3.2 [95% CI: 1.1–9.4]a
Hospitalisation and GP visits
Best et al., 2013 [22] NS Delirium related DBI 0–1 OR: 1.43 [95% CI: 0.79–2.62]
S Delirium related DBI [≥1] OR: 2.95 [95% CI: 1.34–6.51]
NS Fall related DBI 0–1 OR: 1.30 [95% CI: 0.74–2.28]
NS Fall related DBI [≥1] OR: 1.52 [95% CI: 0.70–3.30]
NS Length of stay DBI 0–1 OR: 0.98 [95% CI: 0.59–1.63]
NS Length of stay DBI [≥1] OR: 0.74 [95% CI: 0.37–1.49]
Gnjidic et al., 2014 [33] NS Length of stay AD patients Continuous IRR: 1.06 [95% CI: 0.99–1.12]
S Length of stay non-AD patients Continuous IRR: 1.35 [95% CI: 1.24–1.46]
S No. admissions AD patients Continuous IRR: 1.22 [95% CI: 1.17–1.27]
S No. admissions non-AD patients Continuous IRR: 1.36 [95% CI: 1.28–1.43]
Lowry et al., 2012 [29] S Length of stay Continuous HR: 1.23 [95% CI: 1.06–1.42]
Lönnroos et al., 2012 [36] NS Days per person-year DBI 0–1 RR: 1.10 [95% CI: 0.53–2.28]
NS Days per person-year DBI ≥ 1 RR: 0.80 [95% CI: 0.29–2.22]
Nishtala et al., 2014 [37] S Fall-related hospitalisation DBI > 0 IRR: 1.56 [95% CI: 1.48–1.65]
S GP visits DBI > 0 IRR: 1.13 [95% CI: 1.12–1.13]
Salahudeen et al., 2015 [38] S Hospital
admission
Continuous IRR: 1.36 [95% CI: 1.31–1.42]
S Fall related Continuous IRR: 1.59 [95% CI: 1.46–1.74]
S Length of stay Continuous IRR: 1.50 [95% CI:1.44–1.56]
S GP visits Continuous IRR: 1.26 [95% CI:1.25–1.27]
Falls
Dauphinot et al., 2014 [31] S During hospital stay DBI WHO increase HR: 2.85 [95% CI: 1.14–7.12]
Wilson et al., 2011 [40] S 12-month study period DBI 0–1 IRR: 1.61 [95% CI: 1.17–2.23]
S 12-month study period DBI ≥ 1 IRR: 1.90 [95% CI: 1.30–2.78]
S significant, NS not significant, HR hazard ratio, OR odds ratio, IRR incidence rate ratio, RR relative risk, AD Alzheimer’s disease, DDD defined daily
dose, WHOWorld Health Organisation
a Not adjusted for covariates
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associated with several impairments with regard to mo-
bility, balance difficulty, gait speed, IADL and ADL.
Findings were equivocal for grip strength and chair
stands. Compared to physical function, cognitive function
was less frequently studied. Cognitive function was in-
vestigated in four studies using measures of global
cognition and executive function, e.g. concentration and
planning ability. Tests used were the Mini Mental Status
Examination (MMSE) [24], specific tests [6, 39] or more
extensive neuropsychological test batteries. [28, 35]
Quality of life was also understudied as it was explicitly
addressed in one study [23].
Table 3 Associations between the Drug Burden Index [DBI] and physical and cognitive function, and quality of life
Outcome category S/NS Outcome DBI categorisation Statistic
Physical function and IADL
Cao et al., 2008 [24] S Mobility difficulty Anticholinergics OR: 3.2 [95% CI: 1.5–6.9]
S Slow gait Anticholinergics OR: 3.6 [95% CI: 1.6–8.0]
S Balance difficulty Anticholinergics OR: 4.9 [95% CI: 2.0–12.0]
S Chair stands Anticholinergics OR: 4.2 [95% CI: 2.0–8.7]
S Grip strength Anticholinergics OR: 2.4 [95% CI: 1.1–5.3]
S Upper extremity Anticholinergics OR: 2.7 [95% CI: 1.3–5.4]
S ADL Anticholinergics OR: 3.4 [95% CI: 1.7–6.9]
S Mobility difficulty Sedatives OR: 2.4 [95% CI: 1.1–5.3]
NS Slow gait Sedatives OR: 0.9 [95% CI: 0.4–1.9]
NS Balance difficulty Sedatives OR: 1.7 [95% CI: 0.7–4.0]
NS Chair stands Sedatives OR: 1.8 [95% CI: 0.8–3.9]
S Grip strength Sedatives OR: 3.3 [95% CI: 1.5–7.3]
NS Upper extremity Sedatives OR: 2.0 [95% CI: 1.0–4.2]
NS ADL Sedatives OR: 1.2 [95% CI: 0.6–2.2]
Gnjidic et al., 2012a [25] S 10-m walking speed DBI > 0 B: −0.13 [95% CI: −0.19, −0.08]
S Chair stands DBI > 0 B: 1.11 [95% CI: 1.05, 1.16]
S TUG DBI > 0 B: 1.13 [95% CI: 1.07, 1.19]
S IADL DBI > 0 B: −0.61 [95% CI: −0.84, −0.39]
S ADL DBI > 0 B: −3.21 [95% CI: −4.68, −1.75]
NS Grip strength DBI > 0 B: −0.98 [95% CI: −2.05, 0.08]
Gnjidic et al., 2009 [26] NS Chair stands DBI > 0 B: 0.58 [95% CI: −0.11, 1.27]
S Walking speed DBI > 0 B: −0.03 [95% CI: −0.05, −0.00]
S Narrow walk speed DBI > 0 B: −0.03 [95% CI: −0.05, −0.01]
S Balance difficulty DBI > 0 B: −0.11 [95% CI: −0.18, −0.03]
S Grip strength DBI > 0 B: −1.09 [95% CI: −1.90, −0.28]
S IADL DBI > 0 B: 0.18 [95% CI: 0.04, 0.32]
Gnjidic et al., 2012b [27] S SPPB Continuous B: −1.28 [95% CI: −2.53, −0.04]
NS Grip strength [kg] Continuous B: 0.10 [95% CI: −2.54, 2.74]
Hilmer et al., 2009 [34] S SPPB AUCDB B: −0.08, t value: 2.46, p < .01
S Gait speed AUCDB B: −0.01, t value: −2.86, p = 0.004
S Grip strength AUCDB B: −0.27, t value: −2.87, p = .004
Hilmer et al., 2007 [6] S Health ABC
performance score
Continuous B: −0.15, t value: −5.73, p < .001
Lowry et al., 2012 [29] S Barthel Index Continuous OR: 0.71 [95% CI: 0.55–0.91]
Wilson et al., 2010 [39] S Balance AUCDB sedatives OR: 1.57 [95% CI: 1.08–2.27]
Gnjidic et al., 2012d [32] S Prefrail DBI > 0 OR: 1.62 [95% CI: 1.21, 2.15]
S Frail DBI > 0 OR: 2.14 [95% CI: 1.25, 3.64]
Cognitive function
Cao et al., 2008 [24] S MMSE Anticholinergics OR: 2.4 [95% CI: 1.1–5.1]
NS MMSE Sedatives OR: 1.1 [95% CI: 0.5–2.3]
Gnjidic et al., 2012c [28] NS ACE DBI > 0 OR: 0.98 [95% CI: 0.66–1.47]
NS TMT DBI > 0 OR: 0.71 [95% CI: 0.40–1.24]
NS Cognitive impairment DBI > 0 OR: 1.34 [95% CI: 0.83–2.16]
Hilmer et al., 2007 [6] S DSST Continuous B: −1.51, t value: −2.50, p = .01
Kashyap et al., 2014 [35] S TMT-B Anticholinergic OR: 2.2 [95% CI: 1.1–8.06]a
S Delayed recall Anticholinergic OR: 4.2 [95% CI: 1.8–15.4]
Quality of life
Bosboom et al., 2012 [23] S QoL DBI > 0 B: −4.07 [95% CI: –7.25, −0.89]
S significant, NS not significant, ACE Addenbrooke’s Cognitive Examination, ADL activities of daily living, DSST digit symbol substitution test, IADL
instrumental activities of daily living, MMSE Mini-Mental Status Examination, QoL quality of life, SPPB Short Physical Performance Battery, TMT
Trailmaking Test, TMT-B Trailmaking Test part-B, TUG Time Up and Go test, B unstandardised regression coefficient, OR odds ratio
a Not adjusted for covariates
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Longitudinal studies
Eleven studies reported longitudinal results from eight patient
cohorts. Incidence of outcomes was consistently taken into
consideration, either through studying incidence of falls, frail-
ty, GP visits, hospitalisation, mortality and physical function
during a follow-up period [31–33, 36–38, 40, 41], through
adjusting in the analyses for baseline physical function [34,
39] or through assessing change in cognitive function [35].
Studies with the shortest follow-ups, up to 12 months [36,
39, 40], had low attrition, being 4 and 13%, whereas those
with a longer follow-up had attrition rates that not surprisingly
ranged from 20% in a 2-year follow-up study [32] to ~30% in
a 6-year follow-up study [34]. Although the ‘lost to follow-up’
rate of the latter study was substantial, it was associated with
only minor differential attrition or selective loss to follow-up.
An interesting modification of the DBI was the area under the
curve for drug burden (AUCDB) or the average drug burden
at each point in time multiplied by the time of exposure [34,
39]. This AUCDB enabled researchers to estimate the cumu-
lative long-term exposure to anticholinergic and sedative
drugs.
However, at the same time, the scope of the longitudinal
studies was rather limited. They included registry data about
ultimate outcomes such as mortality [31, 33, 37, 41], hospital
admission, [33, 36–38] and falls [31, 40]. The number of
prospective cohort studies that examined proximal outcomes,
as directly assessed from patients themselves, was limited and
addressed a limited number of outcomes of frailty, physical
function, e.g. gait speed, grip strength, and balance and cog-
nitive function [32, 34, 35, 39].
Discussion
Overall, the studies of the DBI that have been conducted so far
were of good methodological quality. Importantly, in all but
one study, analyses were adjusted for co-morbidity. Although
it is impossible to adjust for all confounding factors, adjusting
for co-morbidity renders it unlikely that positive associations
between the DBI and clinical outcomes simply reflected the
treatment of multiple diseases or disorders with multiple
drugs. The general picture of studies suggested that the DBI
was examined in large to very large samples of older individ-
uals who were diverse with respect to gender, residence and
mean number of medicines prescribed. Exposure to drugs was
in the majority of studies thoroughly ascertained through
assessing medicine packages or dispensing data. Some longi-
tudinal studies also adopted the AUCDB an adaptation of the
DBI suitable for longitudinal research that takes the time of
exposure to anticholinergic and sedative drugs into account.
Differences between patients with high and low DBI values
were adjusted for in analyses.
A large number of studies found associations between the
DBI and relevant clinical outcomes. Impairments of physical
function and IADL were most extensively examined. The
physical measures provided interesting objective ‘proxy mea-
sures’ of fall risk particularly mobility and balance measures.
Outcomes were assessed through medical records, validated
tests or questionnaires. Longitudinal studies often had ade-
quate follow-ups with attrition being either minor or not dif-
ferential. Together, these findings support the use of the DBI
in both research and clinical practice. In research, the DBI
could serve as an important covariate that should be controlled
for when examining, e.g. predictors of falling. In clinical prac-
tice, the DBI may be useful as a screener of frail patients to
identify individuals with high anticholinergic and sedative
exposure which might aggravate their physical and cognitive
impairment. For example, a 1.5- to 3-fold increased risk of
falling was observed for patients with high exposure to anti-
cholinergic and sedative drugs compared to patients with no
such exposure (see Table 2). Such patients are likely to be
eligible for deprescribing interventions such as medication
reviews conducted by pharmacists and general practitioners.
In turn, screening with the DBI could be examined in con-
trolled trials.
We have three suggestions about representativeness and
selection of populations for further research. First, the DBI
has been studied exclusively in older geriatric patient groups.
However, the DBI could also be useful for other vulnerable
but younger patient groups such as patients with psychiatric
disorders and people with severe intellectual disabilities. Like
in geriatric patients, these patients struggle with cognitive im-
pairment. Polypharmacy with psychotropic medication is very
common in people suffering from schizophrenia [42] and de-
pression [43]. Patients often experience a high burden from
the side effects of psychotropic medications [44]. Similar
problems are known in people with severe intellectual disabil-
ities [45, 46]. Second, studies of patients from other parts of
the world including, e.g. China, the Middle East and South
America are also worthwhile to pursue. Third, to further im-
prove the clinical utility of the DBI for older individuals and in
other vulnerable patient groups, more knowledge about the
clinical implications of a certain DBI score is needed. In par-
ticular, whether this also depends on the underlying disease.
DBI scores may carry a higher risk for patients who suffer
from a degenerative disease such as Alzheimer’s disease, be-
cause of the loss of cholinergic neurons and the increased
uptake of anticholinergic drugs in the brain due to increased
permeability of the blood brain barrier [15].
A recommendation about the DBI calculation is that this
should be based on a consensus list of medicines with anti-
cholinergic and sedative properties which will be updated reg-
ularly, e.g. Duran et al. [47] have made attempts for a list of
medications with anticholinergic properties. Also, the current
DBI formula assumes that different drugs contribute linearly
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to the DBI score regardless of their potency. We suggest ex-
ploring the effects of weighing medication with high and low
anticholinergic or sedative potency [15]. Finally, a potential
source of bias is the high mortality rate in frail older people
with high anticholinergic and sedative burden. This makes a
careful examination of ‘differential attrition’ or selective loss
to follow-up, owing to, e.g. baseline frailty, of even greater
importance for cohort studies which enrol frail older people
than for cohort studies in general.
Further research about the relationship between the DBI
and cognitive function is needed. Specifically, for
community-dwelling geriatric patients without dementia or
early dementia as well as patients with psychiatric disorders,
assessment of cognition with a standardised neuropsycholog-
ical examination as was previously done [35] is needed in
addition to an assessment of cognition with the MMSE [24]
which has a diminished capacity to detect early cognitive im-
pairment. [48] An extensive neuropsychological test battery
allows a more sensitive assessment of a wide range of differ-
ent cognitive functions. Furthermore, examination how the
DBI relates to brain function using functional magnetic reso-
nance imaging (fMRI) would be relevant in this regard. [49]
For physical function tests, the opposite may actually be true,
as Wilson et al. [39] argued that these tests might be too dif-
ficult for residents in RACFs who have advanced functional
decline. For people with more advanced physical decline, se-
lection of easier physical tests would be recommended.
Moreover, quality of life could also be assessed [50] as a
measure of general well-being.
This review had several strengths. The most important
strength was our assessment of the methodological quality
of studies using a standardised scale. Another strength was
that the data extraction was reviewed by a second researcher.
A possible limitation of our reviewwas that it was not possible
to conduct a quantitative meta-analysis, because of the limited
number of studies, the wide array of clinical outcomes, the
analysis of the DBI in different ways (i.e. continuous or di-
chotomous) and the use of country-specific minimum daily
doses. Future meta-analyses, preferably individual patient da-
ta meta-analyses, should examine whether differences in study
findings are associated with methodological differences be-
tween studies.
Thus, an accumulating body of evidence supports the valid-
ity of the DBI.What lies ahead are steps towards further refine-
ment of the DBI in longitudinal studies aimed at substantiating
the present body of evidence using an array of clinical out-
comes in geriatric and other relevant patient groups.
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